-
公开(公告)号：EP3230472A1
公开(公告)日：2017-10-18
申请号：EP15866475.5
申请日：2015-12-08
申请人： Myriad Genetics, Inc. , Tesaro Inc.
发明人： WILCOXEN, Keith , LANCHBURY, Jerry , GUTIN, Alexander , TIMMS, Kirsten , ABKEVICH, Victor , WANG, Yan
IPC分类号： C12Q1/68 , G06F19/22 , A61K31/416
CPC分类号： C12Q1/6886 , A61K31/454 , C12Q2600/106 , C12Q2600/158
摘要： This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature to predict response to niraparib. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature to predict response to niraparib are provided.
摘要翻译： 该文件提供了评估样本（例如癌细胞）是否存在同源重组缺陷（HRD）或HRD签名以预测对尼拉帕利布的反应的方法和材料。 例如，提供了用于确定细胞（例如癌细胞）是否含有HRD标签以预测对niraparib的反应的方法和材料。
-
公开(公告)号：EP3862440A1
公开(公告)日：2021-08-11
申请号：EP21162699.9
申请日：2011-06-17
IPC分类号： C12Q1/6827 , A61P35/00 , C12Q1/6886 , G16B20/00
摘要： This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
-
公开(公告)号：EP2794907B1
公开(公告)日：2019-11-13
申请号：EP12860530.0
申请日：2012-12-21
-
公开(公告)号：EP2539468A2
公开(公告)日：2013-01-02
申请号：EP11748075.6
申请日：2011-02-24
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/156 , G06F19/18 , G06F19/20 , G06F19/22 , G06F19/24 , G06F19/34
摘要： The invention relates generally to methods of molecular analysis and particularly to methods of using genetic copy number variations and loss of heterozygosity in the characterization and treatment of disease.
-
公开(公告)号：EP4234711A3
公开(公告)日：2023-09-20
申请号：EP23160447.1
申请日：2015-08-17
IPC分类号： C12Q1/68 , A61P35/00 , C12Q1/6886
摘要： This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
-
公开(公告)号：EP3012329B1
公开(公告)日：2017-10-25
申请号：EP15189527.3
申请日：2011-06-17
CPC分类号： C12Q1/6886 , C12Q1/6827 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G06F19/18 , C12Q2537/16
-
7.发明公开
公开(公告)号：EP3180447A1
公开(公告)日：2017-06-21
申请号：EP15757372.6
申请日：2015-08-17
IPC分类号： C12Q1/68
摘要： This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
摘要翻译： 该文件提供了评估样品（例如癌细胞）中是否存在同源重组缺陷（HRD）或HRD签名的方法和材料。 例如，提供了用于确定细胞（例如癌细胞）是否含有HRD标签的方法和材料。 还提供了用于鉴定具有同源性定向修复缺陷（HDR）的细胞（例如癌细胞）的材料和方法，以及用于鉴定可能对特定癌症治疗方案有反应的癌症患者的材料和方法。
-
公开(公告)号：EP2582847A2
公开(公告)日：2013-04-24
申请号：EP11796544.2
申请日：2011-06-17
申请人： Myriad Genetics, Inc. , Abkevich, Victor , Gutin, Alexander , Timms, Kirsten , Lanchbury, Jerry
CPC分类号： C12Q1/6886 , C12Q1/6827 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G06F19/18 , C12Q2537/16
摘要： This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
-
公开(公告)号：EP3686288A1
公开(公告)日：2020-07-29
申请号：EP20162059.8
申请日：2015-08-17
IPC分类号： C12Q1/68
摘要： This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell ( e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
-
公开(公告)号：EP3660161A1
公开(公告)日：2020-06-03
申请号：EP19199341.9
申请日：2012-12-21
摘要： This document provides methods and materials involved in assessing samples ( e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell ( e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells ( e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.02 秒)
